Duration of response (DOR) for patients in the CHOP B2101J trial and ELIANA global registration trial for tisagenlecleucel (B2202). The graphs include patients who achieved CR in both trials; median follow-up was 18.6 months (range, 2.8-43.5 months) in the B2101J trial and 9.3 months in the B2202 trial (range, 3.1-18.5 months).